Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. SPY

Go back to Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Novavax (NVAX) Announces Initiation of RSV F Vaccine Phase 3 in Older Adults

November 9, 2015 6:56 AM EST

Novavax (NASDAQ: NVAX) announced the initiation of a Phase 3 clinical trial, known as Resolve, of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older).

The Resolve trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 11,850 older adults at 60 sites in the United States.... More